Research progress on the role and mechanism of visfatin in sepsis-related organ injury

doi:10.16352/j.issn.1001-6325.2022.08.1279

Abstract

Abstract: Sepsis is a common acute and critical disease in clinic. Systemic inflammatory response (SIRS) is one of the key mechanisms for the occurrence of sepsis. Visfatin, as an important cytokine, is involved in the occurrence and development of “cytokines storm” caused by sepsis. Recent clinical and basic research have shown that visfatin plays an important role in the occurrence and development of sepsis, and inhibition of visfatin expression can improve the systemic inflammatory response and the damage of lung, heart, liver and other important organs caused by sepsis. Based on the analysis of current clinical and basic research results, visfatin are expected to become an indicator of the severity of sepsis and a potential target for clinical intervention.

Key words: visfatin, sepsis, MODS

CLC Number:

R363

KUANG Zhong-shen, CONG Zhu-kai, WU Chang-yi, YANG Ning, ZONG Ya-nan, GUO Xiang-yang. Research progress on the role and mechanism of visfatin in sepsis-related organ injury[J]. Basic & Clinical Medicine, 2022, 42(8): 1279-1283.

References 26

[1]	Braun DA. Retrospective review of the sepsis definition after publication of sepsis-3[J]. Am J Med, 2019, 132:382-384.
[2]	Karki R, Kanneganti TD. The ‘cytokine storm’:mole-cular mechanisms and therapeutic prospects[J]. Trends Immunol, 2021, 42:681-705.
[3]	Black WB, Zhang LY, Mak WS, et al. Engineering a nicotinamide mononucleotide redox cofactor system for biocatalysis[J]. Nature chemical biology, 2020, 16:87-94.
[4]	Managò A, Audrito V, Mazzola F, et al. Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation[J]. Nat Commun, 2019, 10:4116.doi:10.1038/s41467-019-12055-2.
[5]	Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis[J]. Eur J Immunol, 2002, 32:3225-3234.
[6]	Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:a protein secreted by visceral fat that mimics the effects of insulin[J]. Science, 2005, 307:426-430.
[7]	Nowell M, Evans L, Williams A. PBEF/NAMPT/visfatin:a promising drug target for treating rheumatoid arthritis?[J]. Future Med Chem, 2012, 4:751-769.
[8]	Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis[J]. J Clin Invest, 2004, 113:1318-1327.
[9]	Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE[J]. PLoS One, 2009, 4:e7897.doi:10.1371/journal.pone.0007897.
[10]	Huffaker TB, Ekiz HA, Barba C, et al. A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages[J]. Nat Commun, 2021, 12:2620.doi:10.1038/s41467-021-22923-5.
[11]	Rotllan N, Camacho M, Tondo M, et al. Therapeutic potential of emerging NAD+-increasing strategies for cardiovascular diseases[J]. Antioxidants (Basel), 2021, 10:1939.doi:10.3390/antiox10121939.
[12]	Dakroub A, Suzanne AN, Firas Kobeissy, et al. Visfatin:An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases[J]. J Cell Physiol, 2021, 236:6282-6296.
[13]	Bossardi Ramos R, Adam AP. Molecular mechanisms of vascular damage during lung injury[J]. Adv Exp Med Biol, 2021, 1304:95-107.
[14]	Olszańska J, Pietraszek-Gremplewicz K, Nowak D. Melanoma progression under obesity:focus on adipokines[J]. Cancers (Basel), 2021, 13:2281.doi:10.3390/cancers13092281.
[15]	Bermudez T,Sammani S, Hernon VR, et al. eNAMPT neutralization reduces preclinical ARDS severity via rectified NFκB and Akt/mTORC2 signaling[J].Sci Rep, 2022, 12:696.doi:10.1038/s41598-021-04444-9.
[16]	Song J, Deng T. The Adipocyte and Adaptive Immunity[J]. Front Immunol, 2020, 11:593058.doi:10.3389/fimmu.2020.593058.
[17]	Audrito V, Messana VG, Deaglio S. NAMPT and NAPRT: two metabolic enzymes with key roles in inflammation[J]. Front Oncol, 2020, 10:358.doi:10.3389/fonc.2020.00358.eCollection2020.
[18]	Karampela I, Christodoulatos GS, Kandri E, et al. Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis:a prospective observational study[J]. Cytokine, 2019, 119:62-70.
[19]	Koch A, Weiskirchen R, Krusch A, et al. Visfatin serum levels predict mortality in critically Ⅲ patients[J]. Dis Markers, 2018, 2018:7315356.doi:10.1155/2018/7315356.eCollection2018.
[20]	Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome[J]. Lancet, 2021, 398:622-637.
[21]	Bime C, Casanova N, Oita RC, et al. Development of a biomarker mortality risk model in acute respiratory distress syndrome[J]. Crit Care, 2019, 23:410.doi:10.1186/s13054-019-2697-x.
[22]	Quijada H, Bermudez T, Kempf CL, et al. Endothelial eNAMPT amplifies pre-clinical acute lung injury:efficacy of an eNAMPT-neutralising monoclonal antibody[J]. Eur Respir J, 2021, 57:2002536.doi:10.1183/13993003.02536-2020.Print 2021 May.
[23]	Liu L, Wang P, Liang C, et al. Distinct effects of Nampt inhibition on mild and severe models of lipopolysaccharide-induced myocardial impairment[J]. Int Immunopharmacol, 2013, 17:342-349.
[24]	李文蕾,霍洪亮. Visfatin对心肌细胞炎性因子ICAM-1,VCAM-1表达的影响[D].长春,东北师范大学, 2011, 11:1-40.
[25]	Heo YJ, Choi SE, Lee N, et al. Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model[J]. J Gastroenterol Hepatol, 2021, 36:2592-2600.
[26]	Moschen AR, Gerner R, Schroll A, et al. A key role for Pre-B cell colony-enhancing factor in experimental hepatitis[J]. Hepatology, 2011, 54:675-686.